Aitua Salami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aitua Salami has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Amit R.T. Joshi
Department of Surgery, Einstein Healthcare Network, Philadelphia, Pennsylvania, USA
3 shared publications- Thaer Obaid
Department of Colorectal Surgery, Cleveland Clinic, Weston, FL, USA
2 shared publications Emre Gorgun
Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio, USA
1 shared publicationLuanne Force
Department of Colorectal Surgery, Cleveland Clinic, Weston, Florida, USA
1 shared publicationMichelle Deleon
Department of Surgery, Einstein Healthcare Network, Philadelphia, Pennsylvania, USA
1 shared publicationNkem J. Nweze
Department of Surgery, Einstein Healthcare Network, Philadelphia, Pennsylvania, USA
1 shared publication
Latest Publications
- 29 November 2019
- Published by Wiley in Colorectal Disease
- Vol. 22 (5) , 513-520
Neoadjuvant chemoradiation versus adjuvant chemotherapy for locally advanced adenocarcinoma of the rectosigmoid junction
Background The optimal treatment approach for adenocarcinoma of the rectosigmoid junction remains unclear. Objective To compare outcomes of NCR and AC for cancer of the rectosigmoid junction. Design Retrospective cohort study (2004 – 2015) Setting Nationwide, hospital‐based cancer outcomes data (National Cancer Database). Patients All patients who underwent curative‐intent resection for locally advanced (AJCC stages II & III) adenocarcinoma of the rectosigmoid junction were included. Exclusion criteria were age 75 years, Charlson‐Deyo score>2, AJCC stages I, IV, and un‐staged tumors. Interventions Treatment with NCR versus AC. Main Outcome Measures The primary outcome was overall survival. Other endpoints were resection margin status, the presence of lympho‐vascular invasion, and postoperative length of stay. Results A total of 2,828 patients were included in this study [1,701 (59.7%) received NCR]. NCR was more frequently utilized in patients who were black (10.3% vs 7.6%, pNCR is associated with prolonged hospitalization needs without a clear survival benefit, when compared to AC. Prospective studies are warranted to definitively compare outcomes of NCR and AC in this patient population.
- 29 November 2019
- Published by Wiley in Colorectal Disease
- Vol. 22 (5) , 513-520
Neoadjuvant chemoradiation versus adjuvant chemotherapy for locally advanced adenocarcinoma of the rectosigmoid junction
Background The optimal treatment approach for adenocarcinoma of the rectosigmoid junction remains unclear. Objective To compare outcomes of NCR and AC for cancer of the rectosigmoid junction. Design Retrospective cohort study (2004 – 2015) Setting Nationwide, hospital‐based cancer outcomes data (National Cancer Database). Patients All patients who underwent curative‐intent resection for locally advanced (AJCC stages II & III) adenocarcinoma of the rectosigmoid junction were included. Exclusion criteria were age 75 years, Charlson‐Deyo score>2, AJCC stages I, IV, and un‐staged tumors. Interventions Treatment with NCR versus AC. Main Outcome Measures The primary outcome was overall survival. Other endpoints were resection margin status, the presence of lympho‐vascular invasion, and postoperative length of stay. Results A total of 2,828 patients were included in this study [1,701 (59.7%) received NCR]. NCR was more frequently utilized in patients who were black (10.3% vs 7.6%, pNCR is associated with prolonged hospitalization needs without a clear survival benefit, when compared to AC. Prospective studies are warranted to definitively compare outcomes of NCR and AC in this patient population.
- 1 January 2019
- Published by Elsevier in The American Journal of Surgery
- Vol. 217 (1) , 103-107
Trends in the clinical presentation, treatment, and survival for pancreatic adenocarcinoma
- 1 January 2019
- Published by Elsevier in The American Journal of Surgery
- Vol. 217 (1) , 103-107
Trends in the clinical presentation, treatment, and survival for pancreatic adenocarcinoma